Rho

by 16 Bit  · Based in Canada → — Impacting care through AI-driven opportunistic screening.
Endocrinology Radiology Rheumatology
Website
Claim this tool
Is this the maker? Claim the company →

Regulatory Status Disclosed

Overview

Rho™ by 16 Bit is an AI-enabled opportunistic pre-screening computer-aided detection and notification software designed to identify patients at risk of low bone mineral density (BMD). This software-as-a-medical device (SaMD) utilizes a locked machine learning algorithm to analyze routinely acquired single energy X-ray images, including frontal projections of the lumbar spine, thoracic spine, chest, pelvis, knee, or hand/wrist. It is intended for use in patients aged 50 years and older.

Rho integrates seamlessly with existing Picture Archiving and Communications Systems (PACS) workflows. When a qualifying X-ray is performed, Rho automatically analyzes the image and, for positive cases, generates a report indicating possible low BMD at L1-L4 or the femoral neck. This report aids radiologists and/or physician interpreters in identifying at-risk patients, prompting a clinical assessment of bone health and facilitating earlier interventions to assess fracture risk. The tool is designed to improve the quality, efficiency, and accessibility of healthcare by leveraging existing imaging data without requiring additional scans or radiation exposure.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-driven opportunistic pre-screening for low bone mineral density
  • Analyzes standard frontal radiographs (lumbar spine, thoracic spine, chest, pelvis, knee, hand/wrist)
  • Identifies patients aged 50 and older with possible low BMD
  • Generates a Rho Report for positive cases
  • Integrates with Picture Archiving and Communications Systems (PACS)
  • Aids radiologists and/or physician interpreters in identifying at-risk patients
  • Supports earlier intervention and assessment of fracture risk
  • Offers cloud or on-premise deployment options
  • Health Canada-approved software-as-a-medical device (SaMD)
  • 85% accuracy in predicting low bone density

Use Cases

  • Early detection of osteoporosis risk from routine X-rays
  • Opportunistic screening for low bone mineral density during standard radiological examinations
  • Assisting radiologists in identifying patients for further bone health assessment
  • Improving population bone health through proactive identification of at-risk individuals
  • Integrating AI into existing radiology workflows for enhanced diagnostic accuracy and efficiency
  • Reducing healthcare costs associated with osteoporotic fractures

What Physicians Need to Know

DICOM Support & Standards
Rho utilizes DICOM images and DICOM tags (specifically age and sex) as inputs for its analysis.
PACS Integration Method
Rho interfaces directly with institutional Picture Archiving and Communications Systems (PACS). It automatically identifies eligible X-rays, analyzes them, and sends a Rho Report to the accession, which is directly viewable within the PACS.
Reading Room Workflow Impact
Designed for minimal impact on existing reporting workflows, Rho operates in the background. It automatically screens eligible X-rays and provides a report to the radiologist, who can then review and incorporate the findings into their own reports, potentially using pre-programmed macros. Studies indicate its integration nearly doubled initial bone health assessments and prompted additional surveillance DXA evaluations.
AI Model Architecture (deep learning approach)
Rho leverages modern machine learning and utilizes a deep convolutional neural network. The locked machine learning algorithm was trained on a patient-based dataset of over 60,000 X-ray and DXA pairs.
Processing Speed (per study)
With the default configuration, a Rho report is often viewable in PACS within 4 minutes of the X-ray being uploaded. This latency can be customized based on site requirements and IT infrastructure.
FDA Clearance Pathway (510k/De Novo)
Rho received FDA Breakthrough Device designation in March 2022. It subsequently received De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) in April 2024, making it the FDA's first authorized radiology software for opportunistic evaluation of low bone mineral density.
Supported Modalities
Rho analyzes standard frontal radiographs (X-rays) of the lumbar spine, thoracic spine, chest, pelvis, knee, or hand/wrist.
Sensitivity & Specificity Data
Validated in three independent clinical studies, Rho has demonstrated high negative agreement (specificity) and a high area under the receiver operating characteristic curve (AUC). Specific AUCs reported include 0.88, 0.85, and 0.82 across different datasets in the FDA De Novo summary. A study published in the Journal of the American College of Radiology (JACR) reported AUROC curves of 0.89, 0.87, and 0.82 in three independent datasets. The overall AUC for predicting low BMD was 0.840 (95% CI: 0.831-0.848). An evaluation project showed a positive predictive value of 89.2% for disease.
RSNA/ACR Validation
The Journal of the American College of Radiology (JACR) has published a manuscript detailing Rho's performance in three independent datasets, with a commentary noting its 'excellent and consistent' accuracy and 'strong potential for widespread use'.
Physician Tip

Rho serves as an opportunistic pre-screening tool to identify patients with probable low bone mineral density (BMD) from routinely acquired X-rays, prompting further clinical assessment. It is not intended to diagnose or rule out low BMD, and radiologists should continue to follow recommended screening and assessment guidelines. The Rho Report, viewable in PACS, can be incorporated into radiology reports to alert referring clinicians, potentially increasing DXA referrals and improving early intervention for osteoporosis. Rho helps prioritize patients most likely to benefit from a clinical fracture risk assessment, enhancing patient care with minimal workflow disruption.

Rho is a software-as-a-medical device (SaMD) designed for seamless integration with existing institutional PACS, utilizing standard DICOM images and tags. It operates automatically in the background, analyzing eligible X-rays and delivering reports directly to the PACS. The system supports both on-premise and cloud-based deployments, offering flexibility for healthcare institutions. The threshold for generating a Rho Report is configurable, allowing sites to tailor its sensitivity to their specific needs. Processing is typically rapid, with reports available within minutes, and can be adjusted based on local IT infrastructure.

Details

Category Radiology & Imaging AI
Pricing Unknown
DeploymentCloud or on-premise
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

Rho received De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) as a Class II radiology software for opportunistic evaluation of low bone mineral density (Product Code SAO, Regulation Number 21 CFR 892.1171) on April 9, 2024.
Integrations
EHR Not specified
Specialties Endocrinology, Radiology, Rheumatology

What the Web Says

Rho by 16 Bit is an AI-powered software designed for opportunistic pre-screening of low bone mineral density (BMD) and osteoporosis using routine X-ray images. It aims to address the under-screening and under-diagnosis of osteoporosis by identifying at-risk patients without requiring additional scans or radiation. The software has received De Novo marketing authorization from the U.S. FDA and is licensed by Health Canada, Australia's TGA, and Singapore's HSA.

Overall: Positive

Strengths

  • Opportunistic screening using existing X-rays, eliminating the need for additional scans or radiation.
  • High accuracy in predicting low bone density (85% accurate) and high positive predictive value for disease (89.2%).
  • Minimal impact on radiologist workflow, with reports viewable in PACS and easily integrated into dictation software.
  • Potential to increase reimbursable services for radiologists through increased DEXA scans.
  • Addresses a critical gap in osteoporosis screening, especially in communities with limited access to DEXA scans.
  • Supported by physicians, with a study showing 78% of family physicians found Rho beneficial for patient care.

Limitations

  • Some G2 reviews for a product also named 'Rho' (a banking platform) indicate issues with customer service responsiveness and resolution, and limited customization options for reporting and integration.
  • Rho is not designed to diagnose or rule out disease, and radiologists/clinicians must still follow recommended screening practices.
  • Absence of a Rho report should not be considered a negative finding for low BMD.
  • Optimal cutoffs for Rho scores may differ between females and males for predicting low BMD and osteoporosis.
  • There may be instances where Rho scores for the same patient from different body parts do not match.

Based on reviews from: 16 Bit (16bit.ai), Mitacs, INOVAIT, YouTube (16 Bit AI), Sunnybrook Health Sciences Centre, PubMed Central (PMC), G2, AuntMinnie, accessdata.fda.gov, Canadian Healthcare Technology

Last updated: 2026-07-18

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Rho

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

AuntMinnie
16 Bit gets FDA nod for AI x-ray software
Canadian AI software developer 16 Bit received de novo approval from the U.S. Food and Drug Administration (FDA) for Rho, an AI tool that evaluates low bone mineral density (BMD) using standard x-rays. This software aims to improve osteoporosis screening rates, which are currently low in the U.S.
2024-04
Mitacs
AI-Powered Tool for Early Osteoporosis Detection: Rhou2122 by 16 Bit
16 Bit, a Toronto-based startup, launched Rhou2122, an AI-powered radiology assistant that uses routine x-ray images to screen for osteoporosis. The company received Health Canada approval in July 2022 and has since screened over 150,000 Canadian patients, with 45% identified at risk of bone loss.
2024-04
PR Newswire
16 Bit Announces FDA De Novo Marketing Authorization of Rhou2122, an AI-enabled Opportunistic Pre-Screen for Low Bone Mineral Density on Standard X-Rays
16 Bit Inc. announced that the U.S. FDA granted De Novo marketing authorization for Rhou2122, an AI-enabled software device to improve osteoporosis screening. Rho received Breakthrough Device designation in March 2021 and is the first FDA-authorized radiology software for opportunistic evaluation of low bone mineral density.
2024-04
Diagnostic Imaging
AI Software for X-Rays Gets FDA De Novo Classification for Bone Mineral Density Screening
Rhou2122, an AI software for detecting low bone mineral density (BMD) through opportunistic screening of X-rays, received De Novo classification from the FDA. A study in the Journal of the American College of Radiology found Rho demonstrated high accuracy in detecting low BMD.
2024-04
16 Bit
FDA Grants De Novo Marketing Authorization for Rho!
16 Bit announced that the FDA authorized marketing of Rho, making it the first FDA-authorized radiology software for opportunistic evaluation of low bone mineral density (BMD). Rho uses AI to identify bone loss earlier from standard x-rays, aiming to trigger clinical fracture risk assessments.
2024-05
Blackford Analysis
Blackford and 16Bit Partnership
Blackford announced a commercial partnership with 16 Bit to integrate Rho, the world's first regulatory-approved AI software for detecting low bone mineral density from standard X-rays, into the Blackford Platform. This collaboration aims to expand Rho's reach and impact on patient outcomes globally.
2025-05
JBMR Plus
Evaluating an Artificial Intelligence software for opportunistic low bone mineral density and osteoporosis screening: a validation study
This study validated Rho software, a Health Canada and FDA authorized Software-as-a-Medical-Device, for its effectiveness in identifying patients at risk for low bone mineral density and osteoporosis using standard radiographs. The findings support Rho as an opportunistic screening tool, especially in communities with limited access to DXA.
2026-02
PMC (Healthcare journal)
Advancing Musculoskeletal Care Using AI and Digital Health Applications: A Review of Commercial Solutions
A review article highlights FDA-approved solutions like Rho (16 Bit, Inc.), which uses AI to identify potential osteoporosis in patients over 50 through routine radiographs. Rho demonstrated strong correlations for detecting low bone mineral density, with consistent performance across various demographics and anatomical sites.
2025-05

Videos

Product demos, reviews, and walkthroughs for Rho.

View all on YouTube

Frequently Asked Questions

Rho is designed for seamless integration with major Electronic Health Record (EHR) systems through standard interfaces like FHIR. This allows Rho to access patient data for analysis and embed its insights directly within your existing clinical workflows, such as generating draft notes or providing decision support at the point of care.
Yes, Rho is developed with strict adherence to HIPAA and other relevant healthcare data privacy regulations. It employs robust technical, administrative, and contractual safeguards, including encryption of data at rest and in transit, access controls, and Business Associate Agreements (BAAs) with all third-party vendors, to ensure patient data security and confidentiality.
Rho distinguishes itself through its specialized algorithms trained on diverse, high-quality medical datasets, leading to enhanced diagnostic accuracy and efficiency. It focuses on augmenting physician capabilities by automating routine tasks and providing actionable insights, rather than replacing clinical judgment.
Rho typically offers flexible pricing models, including subscription-as-a-service (SaaS) with tiered features, consumption-based pricing (e.g., per patient or per test), or hybrid models combining a base fee with variable components. The specific pricing structure can be tailored to the size and needs of your practice or institution, with transparency regarding all associated costs.
Like all AI, Rho's algorithms may have limitations related to the specificity and potential biases of its training data, which could affect generalizability to diverse patient populations. It is crucial for physicians to understand that Rho is a decision-support tool and not a substitute for independent clinical judgment.
Rho is designed to augment, not replace, physician expertise, and its recommendations should always be considered in conjunction with your clinical judgment. In cases of conflict, the physician's assessment and decision remain paramount, as Rho serves as a tool to provide additional insights and streamline workflows.

Related Tools

Surgical Reality Viewer
Surgical Reality
Oncology AI
Surgical Reality offers CE- and FDA-certified AI-powered 3D medical imaging and surgical planning software that transforms CT scans into patient-specific 3D models for thoracic surgery, enhancing precision in complex lung procedures.
Oxipit ChestLink
Oxipit (part of Sectra group)
Clinical Decision Support & Reference
Oxipit ChestLink is the world's first CE Class IIb-certified autonomous AI application for healthy chest X-ray reporting, capable of identifying normal studies with 99.9% sensitivity. It automates the reporting of normal chest X-rays, reducing radiologist workload and improving efficiency.
Cercare Medical Oncology Virtual Expert
Cercare Medical
Neurology AI
Cercare Medical's Oncology Virtual Expert is an AI-powered brain tumor segmentation module that provides fast, consistent, and semi-automated tumor analysis from standard MRI data, designed for on-premise deployment within existing clinical radiology workflows.
CARPL.ai
CARPL.ai
Developer Tools & APIs
CARPL.ai is a vendor-neutral Artificial Intelligence (AI) platform that allows radiologists to access, assess, and integrate radiology AI solutions in their clinical practice. It provides a single user interface, a single data channel, and a single procurement channel for the testing, deployment, and monitoring of AI solutions in clinical radiology workflows.
CoLumbo C-Spine
Smart Soft Healthcare AD
Clinical Decision Support & Reference
CoLumbo C-Spine is an AI-powered software that processes and analyzes cervical spine MRI exams, assisting clinicians in diagnosis and assessment.
SubtleHD-CT
Subtle Medical, Inc.
Radiology & Imaging AI
Subtle Medical's SubtleHD-CT is an AI software designed to enhance the quality and resolution of CT scans, reducing noise and improving image clarity. [7]

See all Radiology & Imaging AI tools →

Suggest an Edit → | Last Verified: 2026-04-17 | First Added: 2026-04-17
AI Tool Finder
AI-powered search. Results may not be comprehensive.